| Quarter (USD) | Sep 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 16.17 mm | 16.17 mm | 16.17 mm | 16.17 mm | 16.17 mm | 16.17 mm |
| Cash burn (monthly) | (no burn) | 1.83 mm | 10.86 mm | 14.30 mm | (no burn) | 9.04 mm |
| Cash used (since last report) | n/a | 5.10 mm | 30.31 mm | 39.94 mm | n/a | 25.25 mm |
| Cash remaining | n/a | 11.06 mm | -14.15 mm | -23.77 mm | n/a | -9.08 mm |
| Runway (months of cash) | n/a | 6.1 | -1.3 | -1.7 | n/a | -1.0 |
| 13F holders | Current |
|---|---|
| Total holders | 115 |
| Opened positions | 44 |
| Closed positions | 23 |
| Increased positions | 30 |
| Reduced positions | 22 |
| 13F shares | Current |
|---|---|
| Total value | 292.08 bn |
| Total shares | 59.41 mm |
| Total puts | 141.60 k |
| Total calls | 518.20 k |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| venBio Partners | 9.70 mm | $58.49 bn |
| FMR | 7.81 mm | $47.12 bn |
| venBio Global Strategic Fund II | 5.27 mm | $162.11 mm |
| Vivo Capital | 4.22 mm | $25.45 bn |
| Redmile | 4.04 mm | $24.34 bn |
| Vivo Capital IX | 4.03 mm | $124.14 mm |
| Vestal Point Capital | 3.60 mm | $21.71 bn |
| BLK BlackRock | 2.69 mm | $16.21 bn |
| MPM Oncology Impact Management | 2.18 mm | $13.15 bn |
| Orbimed Advisors | 1.89 mm | $11.42 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 Dec 24 | Lettmann Jason | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.66 | 200,000 | 332.00 k | 200,000 |
| 2 Dec 24 | Shelly Pinto | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.66 | 150,000 | 249.00 k | 150,000 |
| 2 Dec 24 | Hemrajani Rekha | Common Stock | Buy | Acquire P | No | No | 1.5468 | 30,000 | 46.40 k | 33,000 |
| 18 Nov 24 | Alan B. Sandler | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.22 | 600,000 | 732.00 k | 600,000 |
| 14 Aug 24 | Jaume Pons | Common Stock | Sell | Dispose S | No | No | 2.58 | 1,937 | 5.00 k | 591,510 |
